Drug intelligence / Profile preview

Ziyedan

Development stage: Phase 4
Lead developer: Beijing Handian Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Ziyedan (紫叶丹) is a traditional Chinese herbal medicine formulation, primarily available as a capsule. It is used for the treatment of chronic hepatitis B and has also been approved in China for the management of flank pain. The main active ingredient or herbal basis appears to be "Zizhu" (紫珠), though detailed composition information is not provided in the available sources. Clinical studies have focused on its efficacy and safety in improving viral response, serological markers, biochemical indices, and clinical symptoms in patients with chronic hepatitis B[1][2][3]. The mechanism of action has not been clearly elucidated or specified in public sources; as an herbal medicine, it may exert multi-target effects typical of traditional Chinese medicinal products.

Brand names: Ziyedan紫叶丹胶囊
Other names: 紫叶丹Zizhu (紫珠)

Beyond the preview

Go deeper on Ziyedan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ziyedan.